GE Healthcare Receives FDA Approval of First-Ever Software to Help Automate Anesthesia Delivery

End-tidal Control software helps reduce greenhouse gas emissions and costs by cutting anesthetic agent waste. Enables anesthesia providers to set precise targets for oxygen and anesthetic agent. Offers increased workflow efficiencies by reducing the manual inputs providers must enter in delivering agent and oxygen.

GE Healthcare has announced the FDA pre-market approval (PMA) for its End-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System. GE Healthcare is the only manufacturer approved to offer general anesthesia delivery with end-tidal concentration control in the U.S. The company initially released the technology in Europe in 2010 and today, anesthesia providers use Et Control software to care for patients in over 100 countries.

Each year more than 300 million patients worldwide undergo surgical procedures, many of them requiring general anesthesia utilizing inhaled anesthetic agents [1] at a cost of $1.2 billion annually. [2] The Et Control software semi-automates the delivery of anesthesia using software, allowing anesthesia providers to set targets for end-tidal oxygen and anesthetic agent. Once targets are set, the software quickly achieves and maintains those targets, regardless of changes in the patient's hemodynamic and metabolic status. The Et Control software improves anesthesia delivery accuracy and simplifies workflows while reducing drug waste, lowering the cost of care and greenhouse gas emissions.

As compared to the manual process, Et Control software may offer the following benefits:

- A potential 44% decline in greenhouse gas emissions due to more efficient use of anesthetic agents [3]
- Increased accuracy in maintaining the target concentrations of oxygen and anesthetic agents [4]
- 50% reduction in manual keystrokes, helping providers spend less time making adjustments and more time observing the patient [5]
- A potential 27% reduction in operating room costs due to lower anesthetic agent spend
“In the past, we continually adjusted vaporizer setting and fresh gas flow to control inspired concentration in an attempt to achieve and maintain the end-tidal concentration we wanted for our patients. To have direct control of the end-tidal concentration that reflects the drug level in the patient’s blood is a big step forward for our ability to personalize a patient’s care. Additionally, low-flow anesthesia has benefits for hospitals and the environment,” said Dr. Jim Philip, Anesthesiologist and Director of Clinical Bioengineering, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital. Philip, who has been a leading proponent for approval of automated control of inhalation drug administration for years, has also served as a paid consultant for GE Healthcare from April 2020 to December 2021.

“Anesthesia providers in the U.S. will have access to the most advanced anesthesia tools available to improve patient care,” said Eric Ruedinger, General Manager of GE Healthcare’s Anesthesia and Respiratory Care business. “As the long-standing global leader in anesthesia delivery, GE Healthcare invested in the development and clinical validation of this Et Control algorithm, and we are committed to creating clinically relevant solutions that will enhance anesthesia practices into the future.”

The FDA approval was supported by the results from the U.S.-based, multi-center, multi-year MASTER-Anesthesia Trial – with over 200 patients (18 years of age and older) enrolled. The trial evaluated the safety and effectiveness of the Et Control software versus conventional anesthetic gas delivery methods during general anesthesia. With this FDA approval, GE Healthcare will launch the Aisys CS2 Anesthesia Delivery System with Et Control in the U.S in the coming months.

Source: GE Healthcare

Reference:


Published on : Mon, 4 Apr 2022

© For personal and private use only. Reproduction must be permitted by the copyright holder. Email to copyright@mindbyte.eu.